Oncology


Patient-Focused Treatment Decisions in Metastatic Bladder Cancer: A Closer Look at the Integration of Immunotherapy

Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. Before the advent of new treatments in recent years, the basic management of this illness has remained unchanged for decades. Long-term survival for people diagnosed with advanced bladder cancer is poor, with approximately 5% of patients with metastatic bladder cancer surviving for 5 years or more. As the role of the immune system in oncogenesis and therapy has become clearer across cancer types, new approaches emerged with important benefits in metastatic bladder cancer. In particular, immune checkpoint inhibitors such as programmed death-1 (PD-1), PD-ligand 1 (PD-L1), and cytotoxic T lymphocyte–associated protein 4 (CTLA-4) inhibitors have changed the treatment paradigm. Checkpoint inhibitors have shown activity in patients with metastatic bladder cancer in both the second-line and the first-line settings. By preventing the interaction between PD-L1 and PD-1, all of these new options can allow the immune system to be more active against tumor cells. As immune checkpoint blockade inhibitors in the treatment of advanced bladder cancer have demonstrated significant enhancements to clinical outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2019

Assessing the Value of Biosimilars: The Current and Future Impact on Patient Outcomes

Biologic agents have revolutionized the treatment of many diseases, including breast cancer, lung cancer, non-Hodgkin’s lymphoma, hepatitis, inflammatory bowel disease (IBD), rheumatoid arthritis, and many more. Biosimilars are expected to have a significant impact on healthcare but present a unique set of challenges for regulators, clinicians, payers, and consumers. The development of new biologics may be a big step in effectively treating diseases for which there are currently no cures. At present, there are biosimilars for filgrastim, infliximab, etanercept, adalimumab, trastuzumab, and bevacizumab. The FDA looks at biosimilars as a biological product that is similar to a U.S. licensed biological product not including minor differences in clinically inactive components, as well as having no clinically meaningful differences between the biological product and the reference product in terms of the safety, efficacy and potency of the product. Recent and upcoming patent expirations for some of the most commonly used biologic agents have led to the development of biosimilar products. Evidence suggests that clinicians need to be continually educated about the multiple aspects of biosimilars, including the underlying scientific principles, the development and regulatory pathways, how to use them in clinical practice, as well as educating their patients about their value.
Physician, Nursing and CMCN credits valid to August 1, 2019

New Agents and Emerging Strategies in Advanced Breast Cancer: Patient-Centric Navigation in the Age of Personalized Care

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity with incidence in the United States being 1 in 8 (about 12 percent). Although death rates have been steadily decreasing over the past 20 years, cure becomes less likely in patients with distant metastases. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (mBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies. Therapy for advanced breast cancer is increasingly personalized, thanks to an array of molecularly targeted/endocrine therapies indicated for recurrent/advanced disease. New classes of targeted agents have been recently introduced or are in development, including PARP inhibitors. The complexities of today’s more personalized care pose multiple challenges to effective clinical and economic management of the disease.
Physician, Nursing and CMCN credits valid to August 1, 2019

Personalized Treatment Strategies in the Management of Metastatic Colorectal Cancer (mCRC)

Colorectal cancer is the development of cancer from the colon or rectum (parts of the large intestine) and is the third most common cancer diagnosed in both men and women in the United States. Colorectal cancer, when discovered early, is highly treatable however, when the disease has metastasized, treatment and management become much more difficult. Metastatic colorectal cancer (mCRC) carries a poor prognosis, with a 5-year survival rate of approximately 70% for regional metastases and 13% for distant metastases. The prognosis of patients with mCRC has significantly improved in recent years with the introduction of inhibitors of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. Patients with stage one cancer typically have surgery as the main or first treatment while those with mCRC are treated with chemotherapy and/or targeted therapies, both alone and in combination.
Physician, Nursing and CMCN credits valid to August 1, 2019

Effective Management of Chemotherapy-Induced Nausea and Vomiting (CINV): Appropriate
Treatment for Improved Outcomes

Chemotherapy-induced nausea and vomiting (CINV) is a condition in which patients become physically ill following the administration of chemotherapy drugs and is one of the most feared side effects of chemotherapy treatments. Patients who suffer from acute CINV typically experience symptoms within the first 24 hours following treatment while delayed CINV usually occurs within 24 to 72 hours after chemotherapy and can potentially last for several days. Risk factors for this condition fall into patient-specific and therapy-specific categories thus the treatment of CINV can vary depending on the patient’s response to the therapy introduced after chemotherapy. Utilizing an appropriate degree of prophylaxis for the first cycle of chemotherapy is critical to prevent breakthrough CINV, which is difficult to manage and can lead to later anticipatory vomiting during subsequent cycles of therapy. The goal of selecting optimal antiemetic therapy continues to be based on the patient’s individualized treatment plans with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of CINV. Optimizing antiemetic usage requires awareness of available and emerging agents, as well as of the unique characteristics of these therapies that affect their role in CINV management. Because antiemetic medication has such a high success rate, chemotherapy patients no longer have to accept nausea, vomiting, and a decreased quality of life as an automatic consequence of treating cancer.
Physician, Nursing and CMCN credits valid to August 1, 2019

The Value of Personalized Treatment Sequencing for Castration-Resistant Prostate Cancer

Prostate cancer is the most commonly diagnosed noncutaneous cancer in men in the US and remains the second leading cause of cancer deaths among American men. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. CRPC occurs when patients’ disease progresses despite castrate levels of testosterone. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with CRPC have been produced and are being used to better treat the disease. The measurement of PSA level has also recently improved the diagnosis of prostate cancer and is used to monitor for disease recurrence. If the level of PSA is a high value, the more likely is the existence of this tumor. Since the approval of docetaxel, five additional therapeutic agents showing a survival benefit have been approved by the FDA in clinical trials. These include enzalutamide and abiraterone acetate, two agents designed specifically to affect the androgen axis; sipuleucel-T, which stimulates the immune system; cabazitaxel, a chemotherapeutic agent; alpharadin (or radium Ra 223 dichloride), an alpha particle-emitting radioactive therapeutic agent; and the new generation antiandrogen agent enzalutamide. These agents have been tested in multiple disease stages of prostate cancer to determine whether or when patients might benefit from each treatment.
Physician, Nursing and CMCN credits valid to August 10, 2019

Best Practices in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC): Individualizing Therapy for Optimized Patient Outcomes

Lung cancer is the second most common cancer and is by far the leading cause of cancer death among men and women, according to the American Cancer Society. More people die of lung cancer than of colon, breast, and prostate cancers combined. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. NSCLC is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Historically, treatment has included a variety of modalities such as surgery, chemotherapy, and radiotherapy. More recently, therapeutic options for NSCLC have evolved to include targeted agents to individualize treatment for patients with advanced disease. This includes treatment options for patients with EGFR mutation–positive NSCLC. and these options may help increase prognosis and quality of life in NSCLC patients. Molecular testing has now become a critical part of selecting treatment for patients with advanced NSCLC. Nearly two-thirds of NSCLC patients who are EGFR mutation-positive and experience disease progression after being treated with an EGFR-TKI develop a T790M resistance mutation, for which there have been limited treatment options.
Physician, Nursing and CMCN credits valid to July 31, 2019

Advances in the Management of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Closer Look at the Integration of Immunotherapy

Head and neck squamous cell carcinoma (HNSCC) affects the mouth, throat, and nasal cavity. The prognosis is fatal once the cancer metastasizes, giving patients, on average, about 5 years to survive. Symptoms may range from mouth ulcers, bleeding or pain the mouth, chronic sinus congestion, sore throat, pain when swallowing, and difficult breathing. Thankfully novel treatments in immunotherapies have proven efficacious, providing an increased survival rate and improved quality of life for patients.
Physician, Nursing and CMCN credits valid to June 30, 2019

Novel Treatment Strategies in the Management of Ovarian Cancer: A Closer Look at the Role of PARP Inhibitors

According to the National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER) there will be an estimated 22,440 new cases of ovarian cancer this year in the United States. The five-year survival rate is approximately 45%, leading to an estimated 14,080 deaths in the US. Ovarian cancer is usually found in stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen. This is due in large part to a lack of symptoms during the earlier stages. The treatment paradigm has exploded in the past three years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in ovarian cancer include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.
Physician, Nursing and CMCN credits valid to June 30, 2019

New Frontiers in the Management of Hepatocellular Carcinoma (HCC): Exploring Novel Treatment Advances and Approaches

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for about 90% of cases of primary liver cancer in the United States. The prevalence and mortality rate of liver cancer has been rising steadily over the past decade and is still increasing as death rates are rising faster than any other type of cancer. Prognosis is especially poor for those with unresectable HCC. Fortunately, new agents have become available for the first time in almost 10 years, including targeted therapies such as Tyrosine Kinase Inhibitors (TKIs). These regimens have shown the ability to improve safety and efficacy outcomes, especially in patients with disease progression and may fulfill the unmet need of treatment, particularly beyond first-line setting.
Physician, Nursing and CMCN credits valid to August 1, 2019

New Horizons in the Treatment and Management of Lymphoma: Novel Therapies for Improved Patient Outcomes

Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma (NHL) in the Western Hemisphere. No sex preponderance is seen for follicular lymphomas, but the incidence increases with age and varies across racial groups. With current therapy options, prognosis is favorable, with median overall survival (OS) exceeding 12 years. There are various treatment options for FL based on the severity of associated symptoms and the rate of cancer growth. Active treatment is started if the patient begins to develop lymphoma-related symptoms or there are signs that the disease is progressing based on testing during follow- up visits. After treatment, many patients can go into a remission that lasts for years; however, this disease should be considered a lifelong condition as relapsed disease can occur. Recent advances in disease management and our understanding of the biology of FL have led to a dramatic change in the treatment landscape. Despite this progress, FL remains incurable with standard therapies but fortunately for patients with FL, several new agents have become available in the past year, including targeted therapy. They have shown the ability to improve safety and efficacy outcomes, especially in patients with relapsed disease that have had other therapies.
Physician, Nursing and CMCN credits valid to June 30, 2019

Novel Treatment Advances and Approaches in the Management of Advanced Renal Cell Carcinoma (RCC)

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. The prognosis for any treated renal cell cancer patient with progressing, recurring, or relapsing disease is poor, regardless of cell type or stage and almost all patients with advanced renal cell cancer are incurable. Fortunately, emerging treatment options, including targeted therapies such as tyrosine kinase inhibitors (TKIs), are being integrated into the advanced RCC treatment paradigm. These newer options individualize therapy for patients with advanced RCC who have progressed on prior therapies, ultimately improving patient outcomes and quality of life. However, the question and selection of further treatment depends on many factors, including previous treatment and site of recurrence, as well as individual patient considerations. In addition, clinicians must analyze and apply evidence-based data and implement updated strategies to manage side effects of newer agents in order to select an appropriate treatment.
Physician, Nursing and CMCN credits valid to June 30, 2019

Challenges and Strategies in an Evolving Chronic Lymphocytic Leukemia (CLL) Treatment Paradigm: What Does Managed Care Need to Know

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow and is the most common type of leukemia in adults. Patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Furthermore, patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. Fortunately for patients with CLL, several new treatments, including targeted therapies, have recently become available, giving clinicians many new options to improve patient outcomes.
Physician, Nursing and CMCN credits valid to April 30, 2019

Novel Insights on the Current and Emerging Treatment Strategies of Castration Resistant Prostate Cancer (CRPC)

Prostate cancer is the most commonly diagnosed non-cutaneous cancer in men in the United States (US) and remains the second leading cause of cancer deaths among American men. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. Screening for CRPC requires measuring PSA levels which are the most common biomarker for prostate cancer. High PSA values indicate an increased probability of the tumor existing. Fortunately, the treatment paradigm has dramatically changed over the past decade with emerging therapies that have shown to improve patient outcomes, survival, and quality of life. Chemotherapy and immunotherapy remain the mainstay of treatment in the first and second line setting while recent advances are being used to better treat the disease, at all stages. Updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, and biomarkers, based on appropriate patient selection criteria, are revolutionizing the way clinicians treat and manage CRPC.
Physician, Nursing and CMCN credits valid to April 30, 2019

Overcoming Real World Challenges in the Management of Metastatic Bladder Cancer: How Advances in Immunotherapy are Improving Patient Outcomes

Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. Long-term survival for patients diagnosed with metastatic bladder cancer is poor, with only 5% of patients surviving for 5 years or more. Due to the role of the immune system in oncogenesis, therapy has become clearer across cancer types, and new approaches are emerging with important benefits in metastatic bladder cancer. In particular, immune checkpoint inhibitors such as programmed death-1 (PD-1), PD-ligand 1 (PD-L1), and cytotoxic T lymphocyte–associated protein 4 (CTLA-4) inhibitors are changing the treatment paradigm. Checkpoint inhibitors have shown efficacy in patients with metastatic bladder cancer in both the second-line setting and the first-line settings. These inhibitors target proteins that are expressed at high levels on some cancer cells, while others target immune cells. All of these new options allow the immune system to be more active against tumor cells. As immune checkpoint blockade inhibitors in the treatment of advanced bladder cancer have demonstrated significant enhancements to clinical outcomes.
Physician, Nursing and CMCN credits valid to March 31, 2019

Patient Focused Treatment Decisions in Metastatic Colorectal Cancer (mCRC): A Closer Look at the Role of Biomarkers in Optimizing Outcomes

Colorectal cancer (CRC) is the development of cancer from the colon or rectum and has the ability to metastasize to other parts of the body. Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. In 2017, it is expected that there will be 134,490 new cases of CRC and 49,190 deaths. CRC is highly treatable when discovered early however metastatic colorectal cancer (mCRC) carries a poor prognosis with only a 5-year survival rate. Fortunately diagnosing CRC has significantly improved in recent years with the introduction of new therapies which are largely based on the stage of the disease, patient medical history and preferences, predictive biomarkers and other factors. Surgery is typically the main treatment in the first line setting however other therapies are needed to effectively treat patients with mCRC to include chemotherapy, targeted therapies, and immunotherapy; both alone and in combination. These options have shown improved efficacy and safety in mCRC and should be integrated into the treatment paradigm. Additionally, treating adverse effects and comorbidities are just as critical to successfully managing the disease, improve patient outcomes and quality of life.
Physician, Nursing and CMCN credits valid to March 31, 2019

Informed Decision Making in Advanced Non-Small Cell Lung Cancer (NSCLC): Expert Strategies for Individualized Treatment

Non-Small Cell Lung Cancer (NSCLC) is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Historically, treatment has included a variety of modalities such as surgery, chemotherapy, and radiotherapy. The recent use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. These recently approved agents could help increase prognosis and quality of life in NSCLC patients. In addition, guidelines from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) have been updated to incorporate a section on maintenance therapy in the management of advanced NSCLC.
Physician, Nursing and CMCN credits valid to March 31, 2019

New Agents and Emerging Strategies in the Management of Hormone Receptor-Positive (HR+) Advanced Breast Cancer: Inhibiting Cellular Signaling Pathways for Improved Therapeutic Outcomes (A Three Part Series)

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 231,840 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2017. The incidence in women in the United States is 1 in 8. About 40,290 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Fortunately for advanced breast cancer patients with hormone receptor-positive (HR+) advanced breast cancer, several new agents have recently become available or are undergoing late stage clinical trials. They have shown the ability to improve safety and efficacy outcomes, especially in the area of HR+, HER2- metastatic breast cancer. This activity will attendees with the appropriate use of new therapies, such as CDK 4/6 inhibitors, through a shared decision-making approach for the treatment of HR+, HER2- metastatic breast cancer, and a solid understanding of the mechanism of action of these therapies.

This three-part program on new horizons in the treatment and management of metastatic breast cancer will provide medical directors, practicing physicians and nurses with the latest clinical data on novel treatments that have recently completed late stage clinical trials. Attendees will be updated on these treatment options and the potential integration of newer agents, in order to optimize the care of their patients.
Physician, Nursing and CMCN credits valid to January 31, 2019

Hormone Receptor-Positive (HR+) Advanced Breast Cancer: Patient-Centric Navigation in the Age of Personalized Care

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 231,840 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2017. The incidence in women in the United States is 1 in 8. About 40,290 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Fortunately for advanced breast cancer patients with hormone receptor-positive (HR+) advanced breast cancer, several new agents have recently become available or are undergoing late stage clinical trials. They have shown the ability to improve safety and efficacy outcomes, especially in the area of HR+, HER2- metastatic breast cancer. This activity will attendees with the appropriate use of new therapies, such as CDK 4/6 inhibitors, through a shared decision-making approach for the treatment of HR+, HER2- metastatic breast cancer, and a solid understanding of the mechanism of action of these therapies. This webinar will be part one of a three-part webinar series that will look closely at HR+, HER2- advanced breast cancer.
Physician, Nursing and CMCN credits valid to January 31, 2019

A Deeper Look into Newer CDK 4/6 Inhibitors in the Management of HR+, HER2- Advanced Breast Cancer: Insight into Clinical Activity and Safety Profiles

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 231,840 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2017. The incidence in women in the United States is 1 in 8. About 40,290 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Fortunately for advanced breast cancer patients with hormone receptor-positive (HR+) advanced breast cancer, several new agents have recently become available or are undergoing late stage clinical trials. They have shown the ability to improve safety and efficacy outcomes, especially in the area of HR+, HER2- metastatic breast cancer. This activity will attendees with the appropriate use of new therapies, such as CDK 4/6 inhibitors, through a shared decision-making approach for the treatment of HR+, HER2- metastatic breast cancer, and a solid understanding of the mechanism of action of these therapies. This webinar will be part two of a three-part webinar series that will look closely at HR+, HER2- advanced breast cancer.
Physician, Nursing and CMCN credits valid to January 31, 2019

Improving Patient Adherence and Quality of Life in HR+, HER2- Advanced Breast Cancer: Strategies for Managing Treatment Related Adverse Events

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 231,840 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2017. The incidence in women in the United States is 1 in 8. About 40,290 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Fortunately for advanced breast cancer patients with hormone receptor-positive (HR+) advanced breast cancer, several new agents have recently become available or are undergoing late stage clinical trials. They have shown the ability to improve safety and efficacy outcomes, especially in the area of HR+, HER2- metastatic breast cancer. This activity will attendees with the appropriate use of new therapies, such as CDK 4/6 inhibitors, through a shared decision-making approach for the treatment of HR+, HER2- metastatic breast cancer, and a solid understanding of the mechanism of action of these therapies. This webinar will be part three of a three-part webinar series that will look closely at HR+, HER2- advanced breast cancer.
Physician, Nursing and CMCN credits valid to January 31, 2019

Evolving Treatment Strategies in the Management of Ovarian Cancer: Expert Perspectives in PARP Inhibition

Ovarian cancer has a poor prognosis as it is usually discovered the late stages of 3 and 4, which means the cancer has already spread or metastasized to other organs. This is due in large part to the lack of symptoms during early stages of development. The 5-year survival rate for patients with ovarian cancer is approximately 45%, however new therapies and guidelines are drastically changing the treatment paradigm. Novel therapies for all types of cancers have exploded in the past 3 years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Current treatments leading the way are include poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in ovarian cancer include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.
Physician, Nursing and CMCN credits valid to January 31, 2019

New Frontiers in the Management of Acute Myeloid Leukemia (AML): Exploring Emerging Treatment Options

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, its incidence is expected to increase as the population ages. Fortunately the treatment paradigm in AML is set to drastically change as many new treatments are on the horizon, including the first novel therapy that has been approved since 1990. This is especially important as AML has several mutation subtypes that influence treatment selection and prognosis. Emerging treatments focus on certain mutations, including FLT3, and have shown improved efficacy and safety outcomes in clinical trial research.
Physician, Nursing and CMCN credits valid to January 31, 2019

New Horizons in the Treatment of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): How Immunotherapies Are Changing the Treatment Paradigm

Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 48,330 new cases are diagnosed annually in the United States, and 9,570 people die of the disease. HNSCC historically has been associated with tobacco and alcohol use; however, during the past decade, infection with high-risk human papillomavirus (HPV) has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in multimodality treatment and a better understanding of head and neck carcinogenesis, survival rates of locally metastatic HNSCC have not substantially improved, and the prognosis for recurrent/metastatic disease remains poor. Fortunately for patients with metastatic HNSCC, new immunotherapeutic options, which have shown improved efficacy and safety, have recently become available to give clinicians and managed care professionals more options when managing a population of metastatic HNSCC patients.
This webinar series on metastatic head and neck squamous cell carcinoma will educate attendees about recently updated clinical practice guidelines of metastatic HNSCC, the latest data on immunotherapies, strategies for integrating these options into the treatment paradigm, options for disease progression, strategies for managing adverse events and what managed care needs to know about immunotherapies in metastatic HNSCC.

Physician, Nursing and CMCN credits valid to November 30, 2018

Integrating Immunotherapies into the Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment Paradigm

Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 48,330 new cases are diagnosed annually in the United States, and 9,570 people die of the disease. HNSCC historically has been associated with tobacco and alcohol use; however, during the past decade, infection with high-risk human papillomavirus (HPV) has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in multimodality treatment and a better understanding of head and neck carcinogenesis, survival rates of locally metastatic HNSCC have not substantially improved, and the prognosis for recurrent/metastatic disease remains poor. Fortunately for patients with metastatic HNSCC, new immunotherapeutic options, which have shown improved efficacy and safety, have recently become available to give clinicians and managed care professionals more options when managing a population of metastatic HNSCC patients. This webinar will be part one of a four-part webinar series that will look closely at integrating immunotherapies into the metastatic HNSCC treatment paradigm.

Physician, Nursing and CMCN credits valid to November 30, 2018

Managing Disease Progression with immunotherapies in Metastatic Head and Neck Cancer: What are the Options when Chemotherapy Fails?

Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 48,330 new cases are diagnosed annually in the United States, and 9,570 people die of the disease. HNSCC historically has been associated with tobacco and alcohol use; however, during the past decade, infection with high-risk human papillomavirus (HPV) has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in multimodality treatment and a better understanding of head and neck carcinogenesis, survival rates of locally metastatic HNSCC have not substantially improved, and the prognosis for recurrent/metastatic disease remains poor. Fortunately for patients with metastatic HNSCC, new immunotherapeutic options, which have shown improved efficacy and safety, have recently become available to give clinicians and managed care professionals more options when managing a population of metastatic HNSCC patients. This webinar will be part two of a four-part webinar series that will look closely at disease progression in metastatic HNSCC, and what options there are when chemotherapy fails.

Physician, Nursing and CMCN credits valid to November 30, 2018

Overcoming Barriers to Treatment in Metastatic HNSCC: Strategies to Manage Adverse Events Associated with Immunotherapies

Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 48,330 new cases are diagnosed annually in the United States, and 9,570 people die of the disease. HNSCC historically has been associated with tobacco and alcohol use; however, during the past decade, infection with high-risk human papillomavirus (HPV) has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in multimodality treatment and a better understanding of head and neck carcinogenesis, survival rates of locally metastatic HNSCC have not substantially improved, and the prognosis for recurrent/metastatic disease remains poor. Fortunately for patients with metastatic HNSCC, new immunotherapeutic options, which have shown improved efficacy and safety, have recently become available to give clinicians and managed care professionals more options when managing a population of metastatic HNSCC patients. This webinar will be part three of a four-part webinar series, and it will look closely at overcoming barriers to treatment in metastatic HNSCC, with a close look and managing immune-related adverse events.

Physician, Nursing and CMCN credits valid to November 30, 2018

What Managed Care Needs to Know in the Evolving Management of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 48,330 new cases are diagnosed annually in the United States, and 9,570 people die of the disease. HNSCC historically has been associated with tobacco and alcohol use; however, during the past decade, infection with high-risk human papillomavirus (HPV) has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in multimodality treatment and a better understanding of head and neck carcinogenesis, survival rates of locally metastatic HNSCC have not substantially improved, and the prognosis for recurrent/metastatic disease remains poor. Fortunately for patients with metastatic HNSCC, new immunotherapeutic options, which have shown improved efficacy and safety, have recently become available to give clinicians and managed care professionals more options when managing a population of metastatic HNSCC patients. This webinar will be part four of a four-part webinar series, and it will look closely at what managed care needs to know the evolving management of head and neck cancer, especially as it relates to immunotherapies.

Physician, Nursing and CMCN credits valid to November 30, 2018

Managed Care Considerations in the Evolving Immuno-Oncology Treatment Landscape

Cancer immunotherapy is the use of the immune system to treat cancer. Immunotherapies can be categorized as active, passive or hybrid (active and passive). These approaches exploit the fact that cancer cells often have molecules on their surface that can be detected by the immune system, known as tumour-associated antigens (TAAs); they are often proteins or other macromolecules (e.g. carbohydrates). Active immunotherapy directs the immune system to attack tumor cells by targeting TAAs. Passive immunotherapies enhance existing anti-tumor responses and include the use of monoclonal antibodies, lymphocytes and cytokines. Advances in the understanding of the immune system are changing the way the interprofessional healthcare team manages cancer. As immunotherapies move to the forefront of cancer treatment, healthcare professionals will need to understand the immune system; know how cancer circumvents it; and be aware of the mechanisms of action, efficacy, and safety of current and emerging immunotherapies. These webinars are designed to educate healthcare professionals on current and emerging scientific data and to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting when managing patients with cancer who are being treated with immunotherapies.
Physician, Nursing and CMCN credits valid to November 30, 2018

Novel Therapies for Improved Patient Outcomes in Metastatic Melanoma

Melanoma is the most serious type of skin cancer and while it is the least common amongst skin cancers, it is by far the most deadly. In the early stages of melanoma, prognosis is usually good for patients but when the melanoma becomes unresectable/advanced and spreads to other areas of the body, prognosis is especially poor. The most common sites of such spread are under the skin (subcutaneous tissue) and other soft tissues (including lymph nodes), the lungs, liver, brain, and bone. Fortunately new therapy options have recently been approved for patients with melanoma. For many years, interleukin-2 (IL-2) was the primary therapy available for patients with advanced melanoma but new immunotherapies have become available. These therapies help the immune system sustain an active response in its attack on melanoma cells. Recently oncolytic viral therapy has also become available for melanoma patients with unresectable disease that has recurred after initial surgery. This session will review these emerging treatment options, their associated risks, and how individualized therapy and patient education can improve patient outcomes.
Physician, Nursing and CMCN credits valid to December 31, 2018

Current Treatment of Advanced Non-Small Cell Lung Cancer

NSCLC is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Historically, treatment has included a variety of modalities such as surgery, chemotherapy, and radiotherapy. More recently, therapeutic options for NSCLC have evolved to include agents such as pemetrexed, gemcitabine, bevacizumab, erlotinib, docetaxel, and cetuximab. Additionally, new options have become available for patients with metastatic squamous NSCLC. The concept of tailoring therapies based on clinical and molecular markers has transformed the management of NSCLC.

Guidelines from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) have recently been updated to incorporate a section on maintenance therapy in the management of advanced NSCLC. Maintenance therapy refers to treatment that prevents a cancer from spreading after it has responded to initial treatments, which has been shown to extend the lives of advanced NSCLC patients.Physician, Nursing and CMCN credits valid to December 31, 2018

Copyright permissions

To the best of our knowledge permissions for use of any copyright materials was received by each individual presenter. NAMCP/AAMCN does receive permissions to record, transcribe and publish materials (slides and audio) from each speaker. These permissions are on file at NAMCP headquarters.

For more information contact Jeremy Williams at 804-527-1905 or jwilliams@namcp.org.

Disclaimer

NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.